Navigation Links
Regeneron Reports First Quarter 2011 Financial and Operating Results
Date:5/3/2011

TARRYTOWN, N.Y., May 3, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2011 and provided an update on development programs and upcoming milestones.  

Clinical Programs UpdateVEGF Trap-Eye (aflibercept ophthalmic solution)– Ophthalmologic DiseasesVEGF Trap-Eye is a fusion protein locally administered in the eye that is designed to bind Vascular Endothelial Growth Factor-A (VEGF-A) and Placental Growth Factor (PlGF), proteins that are involved in the abnormal growth of new blood vessels.  Regeneron maintains exclusive rights to VEGF Trap-Eye in the United States.  Bayer HealthCare LLC has rights to market VEGF Trap-Eye outside the U.S., where the companies will share equally in profits from any future sales of VEGF Trap-Eye.

In February 2011, Regeneron submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD).  In April 2011, the FDA accepted the BLA for filing and granted the Company's request for Priority Review.  Under Priority Review, the target date for an FDA decision on the VEGF Trap-Eye BLA is August 20, 2011.

Also in February 2011, data from the Phase 3 VIEW 1 and VIEW 2 trials of VEGF Trap-Eye in patients with wet AMD and the Phase 3 COPERNICUS trial in macular edema due to central retinal vein occlusion (CRVO) were presented at the Bascom Palmer Eye Institute's Angiogenesis, Exudation and Degeneration 2011 meeting. Results of the Phase 2 DA VINCI trial of VEGF Trap-Eye in diabetic macular edema (DME) were also presented.

In April 2011, Regeneron and Bayer HealthCare announced positive top-line results for VEGF Trap-Eye in the Phase 3 GALILEO study in patients with macular edema due to CRVO.
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Regeneron Announces Presentation at the Bank of America Merrill Lynch 2011 Health Care Conference
2. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
3. Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
4. Regeneron Announces Presentation at the 10th Annual Needham Healthcare Conference
5. Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
6. Regeneron Announces March 2011 Investor Conference Presentations
7. Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration
8. Regeneron Reports Full Year and Fourth Quarter 2010 Financial and Operating Results
9. Regeneron to Webcast Investor Briefing on VEGF Trap-Eye Clinical Program on Sunday, February 13th at 9 am ET
10. Regeneron Announces Presentation at the ISI Annual Conference
11. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting ... China,s orthopedic instrument industry has ... size rising from 3.28 billion yuan in 2006 to ...
(Date:1/15/2014)... AARP Foundation today announced it has established a ... severe cold weather that has gripped much of the nation. ... need; so to support these emergency relief efforts AARP and ... could mean up to $500,000 in aid. The matching program ...
(Date:1/15/2014)... 2014 Shire plc (LSE: SHP, NASDAQ: ... Trading (OFT) approval condition to the announced tender offer for all ... As a result of the waiver, the transaction is no ... tender offer on January 24, 2014 following the currently scheduled expiration ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today ... Friday, June 17, 2011. At the meeting, shareholders approved the ... to increase the total number of authorized shares and authorized ... Therapeutics, Inc. Headquartered in Seattle, CTI ...
... 17, 2011 Unilife Corporation ("Unilife" or the ... Kathleen Merrigan, the Deputy Secretary of the U.S. Department of ... local business leaders at its facility in York, Pennsylvania. ... (WHBC) under the direction of President Obama. The Winning ...
Cached Medicine Technology:Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders 2Unilife Hosts White House Business Council Meeting 2Unilife Hosts White House Business Council Meeting 3
(Date:4/18/2014)... A new article published online in The ... to religious music is associated with a decrease in ... and sense of control over their lives. In particular, ... in anxiety about death and an increase in sense ... and whites, women and men, and individuals of both ...
(Date:4/18/2014)... 2014) Benaroya Research Institute at Virginia Mason (BRI) ... particular molecule in metastatic breast cancer reduces both the ... metastases. BRI scientists have found in models of the ... 60 - 80 percent and can keep the tumor ... million five-year grant comes from the National Cancer Institute ...
(Date:4/18/2014)... A discovery by Northwestern Medicine scientists could lead to ... scarring in people with scleroderma. , Fibrosis, or ... tightening of the skin and lungs can lead to ... The concept for new therapeutic options centers on findings ... Medicine-Rheumatology, who identified the role that a specific protein ...
(Date:4/17/2014)... targets that could be used to provide relief ... London made the discovery when researching how pain ... body. , Dr Marzia Malcangio said: "We have ... and our findings could help chemotherapy patients who ... side effect of some chemotherapy drugs (such as ...
(Date:4/17/2014)... Diego School of Medicine report that older women, plucky ... loss are more likely to be compassionate toward strangers ... in this month,s issue of the International Journal ... associated with better health and well-being as we age, ... the outcomes of individuals whose deficits in compassion put ...
Breaking Medicine News(10 mins):Health News:Religious music brings benefit to seniors' mental health 2Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New clues on tissue scarring in scleroderma 2Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2
... YORK, Feb. 12 Medicare now pays for treatments ... change that and apply a cost-effectiveness standard set by ... Effectiveness Research.The Federal Council is modeled after a U.K. ... This British board approves or rejects treatments using ...
... damage, and study says it,s likely all that sugar , , THURSDAY, ... cans of soda pop daily are almost two times more likely ... to a U.S. study. , But there,s no increased risk for ... drink diet soda. , The researchers analyzed data from 9,358 adults ...
... The Final Inch and Slumdog Millionaire show the challenges ... Astute Oscar-watchers are getting a short ... nominated films that together show the status of this ... four countries where the virus has not been stopped. ...
... ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today announced it ... 19, 2009, and will host a conference call to discuss these ... , , , Date: Thursday, February ... Conference call access:, Internet: www.istavision.com, ...
... got radiation treatment for Hodgkin,s disease are almost 40 times ... findings from five institutions, including the University of Florida. ... researchers report. These women are also likely to develop cancer ... get rid of the cancer. Our second priority is to ...
... Pamper Tired TootsiesBETHESDA, Md., Feb. 12 Valentine,s Day marks ... men and women. While the old adage "a way to ... true, another body part is gaining affection from both sexes ... (APMA) survey revealed 84 percent of women are embarrassed about ...
Cached Medicine News:Health News:2 or More Sodas a Day Boost Women's Kidney Risks 2Health News:Oscar Nominated Films Raise Polio Awareness 2Health News:Pediatric Hodgkin's disease survivors face increased breast cancer risk 2Health News:Pediatric Hodgkin's disease survivors face increased breast cancer risk 3Health News:American Podiatric Medical Association Helps Americans 'Love' Their Feet This Valentine's Day 2Health News:American Podiatric Medical Association Helps Americans 'Love' Their Feet This Valentine's Day 3
... MICROSTAAR injector contains a plunger style advance, ... be resterilized for multiple use. The injector ... accepts only STAAR cartridges. These injectors are ... This system was designed specifically ...
... the fundamental capsulotmy laser - the unique Ultra ... 2855% less energy in air at approximately 1.8 ... This technology eliminates the occurrence of hot ... pitting. , , , Ultra Q ...
... system is an innovative, robust and ... excellent clinical performance. The digital broadband ... the ES500 system deliver excellent tissue ... system offers a full suite of ...
Protects the eye during or after surgery or trauma. 8mm diameter, lint free keeps cornea moist. Protects retina from operating microscope light rays....
Medicine Products: